Emerging Challenges of GLP-1 Agonists in PET-CT Imaging
New research at EANM 2025 highlights how GLP-1 receptor agonists can alter PET-CT scans, potentially leading to misdiagnosis in cancer imaging. Awareness and careful medication documentation are key to accurate interpretation.
Recent research presented at the 38th Annual Congress of the European Association of Nuclear Medicine highlights a growing concern regarding the impact of GLP-1 receptor agonists on PET-CT scans used in oncology. These medications, widely prescribed for type 2 diabetes and weight management—seeing a 700% increase in usage in the U.S. between 2019 and 2023—can alter normal tracer uptake patterns, complicating image interpretation.
GLP-1 receptor agonists influence glucose metabolism, gastric motility, and sympathetic nervous activity. This leads to atypical FDG uptake in tissues such as skeletal muscle, the myocardium, and brown adipose tissue, which may mimic signs of malignancy or inflammation. A retrospective review by Alliance Medical Ltd. revealed several abnormal uptake patterns in patients taking these drugs, which could be misdiagnosed as pathological changes if medication history is not considered.
Dr. Peter Strouhal, Medical Director at Alliance Medical, emphasized the importance of recognizing these patterns. He explained that misinterpretation could cause unnecessary invasive investigations, incorrect cancer staging, and delays in treatment, adding stress to patients. Currently, there are no international guidelines in the UK addressing this issue. The team advises thorough documentation of medication histories but does not recommend stopping GLP-1 therapies before scans, aligning with Australian practices which include fasting and good glucose control.
The researchers plan to expand data collection to strengthen future guidelines and are fostering international collaborations to ensure consistent interpretation worldwide. Ultimately, awareness of these altered uptake patterns aims to improve diagnostic accuracy, reduce unnecessary procedures, and enhance patient care.
Source: https://medicalxpress.com/news/2025-10-glp-agonists-pose-emerging-pet.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Healthcare Workers Address Vaccine Skepticism Amid Romania's Measles Surge
Romania faces a rising measles outbreak driven by low vaccine coverage and misinformation. Healthcare workers are actively fighting vaccine skepticism to protect communities and curb the epidemic.
Patient Satisfaction Grows When AI Complements Human Medical Expertise
A recent study shows that patients and healthcare staff are increasingly accepting AI tools in virtual primary care, provided they complement human expertise and clinical judgment, enhancing efficiency and patient satisfaction.
Adolescent Sleep Patterns as Predictors of Future Heart Health
Early and consistent sleep patterns during adolescence are linked to better cardiovascular health in young adulthood, highlighting the importance of sleep quality and timing for lifelong heart health.
Study Shows Broader Benefits of Flu Vaccination Beyond Protecting the Vaccinated
New research demonstrates that seasonal influenza vaccination offers community-wide protection, reducing infections among both vaccinated and unvaccinated individuals. Learn how widespread vaccination can control influenza outbreaks effectively.